Europe Approves Expanded Indications For Cystistat (Hyaluronic Acid)
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Europe Approves Expanded Indications For Cystistat (Hyaluronic Acid)

LONDON, ON -- September 7, 2000 -- Bioniche Life Sciences Inc, a fully integrated Canadian biopharmaceutical company serving both the human and animal health markets, announced receipt of approval to expand the indications for one of its lead products, Cystistat® (hyaluronic acid), in Europe.

The new indications include radiation cystitis and cystitis caused by infections, trauma, urolithiasis, urinary retention, and neoplasia.

"The European approval for these additional indications marks an important milestone in our development of Cystistat in conjunction with our on-going efforts to secure a U.S. registration," said Dr. Vincent A. Salvatori, Senior Vice President, Clinical Operations. "This approval also represents an important new alternative therapy for urologists and will enhance our reputation as a leading provider of urological therapeutics."

"These expanded indications encompass all forms of cystitis and provide broader opportunities for all of our existing European Cystistat marketing partners," remarked Albert Beraldo, Vice President of Business Development at Bioniche. "With a larger market profile, Bioniche will be better positioned to attract additional quality marketing partners in the remaining regions of Europe." Licensing and distribution agreements are currently in place throughout Europe including the UK, Italy, Scandinavia, Austria and Spain.

Cystistat is Bioniche's patented treatment for Interstitial Cystitis (IC), a painful, debilitating bladder condition that afflicts approximately 1.5 million people worldwide. Manufactured from a highly purified hyaluronic-acid, Cystistat is instilled directly into the bladder where the drug helps to restore the glycosaminoglycan (GAG) layer. Cystistat is manufactured at the Company's FDA/ISO 9001 approved facility in Ireland and is currently approved for distribution in Canada and Europe.

Related Link: Bioniche Life Sciences Inc.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities